Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
Marcus Maurer, William Berger, Ana M. Giménez‐Arnau, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 150, Iss. 6, pp. 1498-1506.e2
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
Allen P. Kaplan, Mark Lebwohl, Ana M. Giménez‐Arnau, et al.
Allergy (2022) Vol. 78, Iss. 2, pp. 389-401
Open Access | Times Cited: 86
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 64
Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment
Torsten Zuberbier, Luís Felipe Ensina, Ana M. Giménez‐Arnau, et al.
The Lancet (2024) Vol. 404, Iss. 10450, pp. 393-404
Open Access | Times Cited: 20
Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell‐mediated diseases
Martin Metz, Pavel Kolkhir, Sabine Altrichter, et al.
Allergy (2023) Vol. 79, Iss. 1, pp. 37-51
Open Access | Times Cited: 30
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Vipul Jain, Ana M. Giménez‐Arnau, Koremasa Hayama, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 2, pp. 479-486.e4
Open Access | Times Cited: 24
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial
Sabine Altrichter, Ana M. Giménez‐Arnau, Jonathan A. Bernstein, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 187-199
Open Access | Times Cited: 13
Mast cells: a novel therapeutic avenue for cardiovascular diseases?
Remo Poto, Gianni Marone, Stephen J. Galli, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 7, pp. 681-698
Open Access | Times Cited: 9
Chronic Spontaneous Urticaria
Pavel Kolkhir, Hanna Bonnekoh, Martin Metz, et al.
JAMA (2024) Vol. 332, Iss. 17, pp. 1464-1464
Closed Access | Times Cited: 8
Mast Cells at the Crossroads of Hypersensitivity Reactions and Neurogenic Inflammation
Ernesto Aitella, Ciro Romano, Lia Ginaldi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 927-927
Open Access | Times Cited: 1
Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment
George Ν. Konstantinou, Marc A. Riedl, Peter Valent, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 1, pp. 94-106
Closed Access | Times Cited: 21
Evidence-based use of antihistamines for treatment of allergic conditions
Sophia Linton, Lubnaa Hossenbaccus, Anne K. Ellis
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 4, pp. 412-420
Closed Access | Times Cited: 20
BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria
Jonathan A. Bernstein, Marcus Maurer, Sarbjit S. Saini
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 5, pp. 1229-1240
Open Access | Times Cited: 18
New insights into chronic inducible urticaria
Melba Muñoz, Lea Kiefer, Manuel P. Pereira, et al.
Current Allergy and Asthma Reports (2024) Vol. 24, Iss. 8, pp. 457-469
Open Access | Times Cited: 6
Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response
Ramón Gimeno, Clara Ribas‐Llauradó, David Pesqué, et al.
Clinical and Translational Allergy (2023) Vol. 13, Iss. 3
Open Access | Times Cited: 15
Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
Gil Yosipovitch, Georgia Biazus Soares, Omar Mahmoud
Dermatology and Therapy (2023) Vol. 13, Iss. 8, pp. 1647-1660
Open Access | Times Cited: 14
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Thomas Dörner, Martin Kaul, Antónia Szántó, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 3, pp. 360-371
Open Access | Times Cited: 14
PTGS2: A potential immune regulator and therapeutic target for chronic spontaneous urticaria
Yihui Chen, Xingxing Jian, Lei Zhu, et al.
Life Sciences (2024) Vol. 344, pp. 122582-122582
Closed Access | Times Cited: 5
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Laura Airas, Robert Bermel, Tanuja Chitnis, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis
Martin Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8122-8140
Open Access | Times Cited: 5
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
The emerging role of Bruton’s tyrosine kinase inhibition in Urticaria Management
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Bruton's Tyrosine Kinase – A New Target for Immune Mediated Inflammatory Diseases?
John D. Isaacs
Seminars in Arthritis and Rheumatism (2025), pp. 152681-152681
Open Access
A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
Ragha Suresh, Collin Dunnam, Dhananjay Vaidya, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 16
Open Access | Times Cited: 12
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Rameshwar S. Cheke, Prashant S. Kharkar
Drug Development Research (2023) Vol. 85, Iss. 1
Open Access | Times Cited: 11
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Erica V. Lin, Ragha Suresh, Melanie C. Dispenza
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 1, pp. 33-42
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top